A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
Terminated · Phase 1 · NCT05904496
Conditions: Advanced Solid Tumors
At a glance
- Research payments reported, 2025
- $354,193
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 44
About the trial
- Sponsor
- BeiGene
- Tested
- BGB-30813 (drug), Tislelizumab (drug)
- Dates
- Started 2023-07-19; completion 2025-08-20
- Results posted
- Not yet
This is a First in Human (FIH) Phase 1, multicenter, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-30813 as monotherapy or in combination with tislelizumab in participants with advanced or metastatic solid tumors. The study will be conducted in 2 parts: Phase 1a dose escalation and Phase 1b dose expansion.
From ClinicalTrials.gov, last updated 2025-09-16. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $354,193 in research payments for this study in 2025 (35 payments).
Products named: Tevimbra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Martin E. Gutierrez, MD Medical Oncology · Hackensack, NJ
- Siqing Fu, MD, PH D Hematology & Oncology · Houston, TX
- Ildefonso I. Rodriguez-rivera, M.D. Hematology & Oncology · San Antonio, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Next Oncology $235,515
- Ut MD Anderson Cancer Center $110,957
- Hackensack University Medical Center, NJ $7,721
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.